Navigation Links
Jubilant and BioLeap Announce New Partnership in Drug Discovery
Date:1/13/2009

NOIDA, India and NEW HOPE, Pa., Jan. 13 /PRNewswire/ -- Jubilant Organosys Ltd., headquartered at Noida, near New Delhi, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a drug discovery partnership with BioLeap, LLC, USA. Under this partnership, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection for multiple therapeutic areas.

Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys, said: "We are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined 'best in class' preclinical drug discovery capabilities."

Gerald Evans, BioLeap Chief Business Officer added, "We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services."

BioLeap's platform technology is completely "in-silico," and it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and/or improve existing molecules without the limitations of library screening, thereby reducing the time and cost of traditional screening methods.

Many current screening programs have hit barriers with regards to finding small molecule candidates for viable validate
'/>"/>

SOURCE Jubilant Organosys Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... Sept. 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... has been shown to be effective in animal models ... alternative to intravenous infusions that could pave the way ... were presented yesterday at the Heart Failure Society of ... Las Vegas . The ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found ... test identifies patients with bone fragility fracture when ... million people worldwide are at risk of fracture ... standard bone strength test, the DEXA bone density ... Society for Bone and Mineral Research Annual Conference ...
Breaking Biology Technology:The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3
... Clemson physics professor Apparao Rao and his team are researching ... us to toxic chemicals or gases in the air. Put ... there for real-time chemical alerts in battle, in industry, in ... build extremely small devices to do this work has been ...
... occurring smallpox was eradicated in 1977, there is concern ... release it into the population. Under such circumstances, the ... administration. In a study published in the December 2008 ... researchers found that lifetime protection is obtained from just ...
... (Gems), a global leader in liquid level, pressure, and flow ... UCL-520 Series of Ultrasonic Level Sensors. The UCL-520 Series is ... management, chemical storage as well as many other challenging fluid ... ...
Cached Biology Technology:Clemson researchers advance nanoscale electromechanical sensors 2New study indicates smallpox vaccination effective for decades 2GEMS Introduces Ultrasonic Continuous Liquid Level Sensor for Challenging Fluid Measurement 2
(Date:9/15/2014)... -- Adding a common epilepsy drug to a morphine ... side effects. Moreover, the combination can reduce the dosage ... a team of pain researchers at Indiana University. , ... with neuropathic pain, a difficult-to-treat condition often felt in ... damage. , "There is a huge unmet need for ...
(Date:9/15/2014)... containing carbon-halogen bonds are produced naturally across all kingdoms ... products with a broad range of biological activities. The ... a profound influence on their molecular properties. ... has been to find the late-stage, site-specific incorporation of ... replacing an sp C-H bond (one of the most ...
(Date:9/15/2014)... of Australia,s leading coral reef ecologists fears that reef ... ecosystem survival that we once thought. , In an ... ARC Centre of Excellence for Coral Reef Studies (Coral ... most important species within reef ecosystems. , In coral ... vital jobs that keep the ecosystem safe and functioning. ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2
... HAMILTON Sept. 1, 2011 McMaster researchers have found ... cells to become bone instead of fat, improving overall health ... body,s mesenchymal stem cells are most likely to become fat ... treadmill-conditioned mice, a team led by the Department of Kinesiology,s ...
... into two hemispheres, which are linked through only a few ... to create a coherent image of our environment our ... unity of our subjective experience, information from both hemispheres needs ... bundle connecting the left and right side of our brain, ...
... DALLAS Sept. 1, 2011 UT Southwestern Medical Center ... at high risk of contracting colorectal cancer, a deadly yet ... UT Southwestern and Parkland Memorial Hospital allows doctors to screen ... uterine cancer patients younger than 55, to determine if there ...
Cached Biology News:Exercise boosts health by influencing stem cells to become bone, not fat, McMaster researchers find 22 brain halves, 1 perception 22 brain halves, 1 perception 3UT Southwestern program identifies families at high risk for colorectal cancer 2UT Southwestern program identifies families at high risk for colorectal cancer 3
... quick turnaround sequencing of individual research samples, ... copy plasmids. Agencourt's world-class, high performance sequencing ... per day. The key benefits of ... 24 48 hour sample turnaround, industry ...
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
...
Biology Products: